FY2023 · ended Mar 31, 2023 · Revenue $0, -100.0% YoY · Filed Aug 30, 2024
Agentix Corp. (AGTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
$0
-100.0% vs prior year
Net income
$-485,636
+14.4% vs prior year
Operating cash flow (TTM)
$-16,530
+93.1% vs year-ago TTM
Free cash flow
—
EPS
$-0.01
+0.0% vs prior year
Dividend per share
None
Shares outstanding
40.07M
+0.0% vs prior year
Net cash
$-47,875
FY 2018
Operating margin
-108092.9%
FY 2022
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGTX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- Dana Point, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1603345
- Former names
- FairWind Energy Inc. (until Jun 27, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Aug 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1,240 |
| Operating income | -$445,187 | -$513,251 | -$744,810 | -$1.4M | -$1.3M |
| Net income | -$485,636 | -$567,048 | -$585,154 | -$1.4M | -$1.3M |
| Diluted EPS | -$0.01 | -$0.01 | — | — | — |
| Operating cash flow | -$108,529 | -$125,078 | -$110,429 | -$88,541 | -$420,982 |
| Total assets | $771 | $100,274 | $106,372 | $261,392 | $51,207 |
| Total liabilities | $3.6M | $3.2M | $2.7M | $2.5M | $606,942 |
| Stockholders' equity | -$3.6M | -$3.1M | -$2.6M | -$2.2M | -$555,735 |
| Cash and investments | $771 | — | — | $12,369 | $1,768 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Jul 1, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 20, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 22, 2025 | Jun 30, 2025 |
| 10-K | Annual report | Jul 16, 2025 | Mar 31, 2025 |
All 153 Agentix Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.